Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

446
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
446
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

159
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
159
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

269
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
269
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

485
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
485
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

252
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
252

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Choline PET/CT in the PSMA Era: Clinical Repositioning, Biological Perspectives, and Emerging Applications.

Diagnostics (Basel, Switzerland)·2026
Same author

Targeting ACKR3/CXCR7 Enhances Platelet Anticoagulant Acylcarnitines and Modulates Procoagulant Function.

Blood·2026
Same author

Standardization of Platelet Activation Tests for the Diagnosis of Heparin-Induced Thrombocytopenia: Communication from the ISTH-SSC Subcommittee on Immune-Mediated Platelet Disorders.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Survey report on functional tests in heparin-induced thrombocytopenia: communication from the ISTH SSC subcommittee on immune-mediated platelet disorders.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Diminished plasma levels of GPIb-<i>α</i> predict mortality in a prospective ARDS cohort.

Frontiers in medicine·2026
Same author

PSMA for HCC: a new frontier in precision medicine for liver cancer?

Cancer treatment and research communications·2026

Related Experiment Video

Updated: Feb 1, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Drug-associated thrombocytopenia.

Tamam Bakchoul1, Irene Marini1

  • 1Transfusion Medicine, Medical Faculty of Tubingen, University of Tubingen, Tubingen, Germany.

Hematology. American Society of Hematology. Education Program
|December 4, 2018
PubMed
Summary

Drug-induced immune thrombocytopenia (DITP) and heparin-induced thrombocytopenia (HIT) are serious conditions. This review updates on their causes, diagnosis, and management, emphasizing prompt recognition and treatment to prevent bleeding and thrombosis.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.1K

Related Experiment Videos

Last Updated: Feb 1, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.1K

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Drug-induced immune thrombocytopenia (DITP) is a significant adverse drug reaction.
  • Heparin-induced thrombocytopenia (HIT) presents with a high risk of thromboembolic complications.
  • Accurate diagnosis of DITP and HIT is challenging due to confounding factors.

Purpose of the Study:

  • To provide an updated review on the pathophysiology of DITP and HIT.
  • To discuss current diagnostic strategies for DITP and HIT.
  • To outline the management principles for DITP and HIT.

Main Methods:

  • Review of current literature on DITP and HIT.
  • Analysis of diagnostic criteria and laboratory tests.
  • Evaluation of treatment guidelines and outcomes.

Main Results:

  • DITP diagnosis relies on clinical presentation and specialized lab tests; treatment involves drug withdrawal.
  • HIT diagnosis utilizes clinical scoring and antibody detection; management requires heparin cessation and alternative anticoagulation.
  • While DITP primarily causes bleeding, HIT is associated with life-threatening thrombosis.

Conclusions:

  • Early identification and appropriate management of DITP and HIT are crucial for patient outcomes.
  • Understanding the distinct mechanisms of DITP and HIT guides therapeutic decisions.
  • Continued research is needed to refine diagnostic and therapeutic approaches for immune-mediated thrombocytopenias.